Telavancin Hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Telavancin Hydrochloride Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
17
Registered trials
20
Result records
7
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Telavancin Hydrochloride can convert its Glycopeptide antibiotic, Cyclic Peptide profile and Peptidoglycan biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Telavancin Hydrochloride (query alias: telavancin) |
|---|---|
| Modality / target | Glycopeptide antibiotic, Cyclic Peptide; Peptidoglycan; Peptidoglycan inhibitors, Cell wall inhibitors |
| Highest global status | Approved |
| Originator | Theravance Biopharma, Inc. |
| Active developers | Cumberland Pharmaceuticals, Inc., Tabuk Pharmaceuticals Manufacturing Co., SciClone Pharmaceuticals (China) Co., Ltd |
The MCP disease footprint includes Pneumonia, Ventilator-Associated, Hospital acquired bacterial pneumonia, Hospital-acquired pneumonia. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT06119061 | Phase 4 | Recruiting | 20 | Determine the CNS penetration of telavancin in critically ill patients with External Ventricular Drainage |
| NCT03172793 | Phase 4 | Completed | 18 | Telavancin Clearance |
| RBR-3p8g7n | Phase 3 | Recruiting | Not disclosed | Not disclosed |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
双重作用机制！塞生药业引进抗生素新药「替拉凡星」在华获批上市
N/A; n=not disclosed; evaluation: 积极. Reported fields: 临床疗效: OR = 1.10(95% CI, 0.82 ~ 1.48); 临床疗效: OR = 1.10(95% CI, 0.82 ~ 1.48)
An Open-Label Study of the Pharmacokinetics of a Single Dose of Telavancin in Pediatric Subjects Aged 12 Months to 17 Years
Phase 1; n=22; evaluation: not stated. Reported fields: Pharmacokinetics- Area Under the Curve Extrapolated to Infinity for the Plasma Concentration Versus Time Curves for Telavancin(Mean) = 229 h*mcg/ml (Standard Deviation, NA); Pharmacokinetics- Area Under the Curve Extrapolated to Infinity for the Plasma Concentration Versus Time Curves for Telavancin(Mean) = 351 h*mcg/ml (Standard Deviation, 79.7); -
Telavancin pharmacokinetics in patients with chronic kidney disease receiving haemodialysis.
Phase 4; n=8; evaluation: not stated. Reported fields: T½ = 13.1 hour
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Telavancin Hydrochloride addresses Pneumonia, Ventilator-Associated, Hospital acquired bacterial pneumonia, Hospital-acquired pneumonia. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Glycopeptide antibiotic, Cyclic Peptide—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 7 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-04-23 | Apotex Completes Previously Announced Strategic Transaction with Cumberland Pharmaceuticals | Approved | Financial terms not disclosed |
| 2025-08-04 | Cumberland Pharmaceuticals Receives Vizient Contract For New Vibativ® 4-Vial Starter Pak | Approved | Financial terms not disclosed |
| 2024-04-01 | Cumberland terminated license and commercialization agreement with Verity Pharmaceuticals for Vibativ in Puerto Rico | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Preparation method of telavancin-loaded positive charge gelatin microspheres”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
